Over the last two years, AbbVie has surpassed EPS estimates 75% of the time and revenue estimates 38% of the time. However, in the last three months, EPS estimates have undergone one upward revision and nine downward revisions, while revenue estimates have experienced one upward revision and seven downward revisions. Quant Ratings classifies AbbVie as a Hold, while Wall Street analysts rate it as a Buy. Year-to-date, the stock has gained approximately 8.28%, outperforming the broader S&P 500 market, which has risen by 6.33%.
Analysts from J.P. Morgan expect seasonal headwinds in the first quarter to impact immunology results, but note that this is reflected in guidance and consensus. They remain optimistic about the portfolio’s long-term prospects, citing the strength of Skyrizi and Rinvoq’s launches in IBD. BMO Capital Markets anticipates typical seasonality impacts for Humira, with an additional low single-digit impact on net price. From a volume perspective, Humira appears to be well-positioned, with first-quarter scripts down 8% year-over-year.
On the other hand, BofA Securities predicts a weaker first quarter for AbbVie, driven by reimbursement challenges leading to lower net pricing and uptake, as well as higher operating expenses due to acquisition costs. Despite these challenges, AbbVie’s long-term growth prospects remain solid, supported by its strong pipeline of new products and its commitment to innovation. Investors will be closely monitoring the company’s earnings results and guidance for insights into its ability to navigate the challenges facing the pharmaceutical industry.
